Optimer Pharmaceuticals (OPTR) Posts Q3 Loss of $0.28, 9c Better than Views
More News related to OPTR
- Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
- Morning Movers 11/12: NLST, HPJ, COMS, AMD, CAAS Higher; TRMS, NWPX, ATRN, BRCD, CDTI, GMCR Lower
- Optimer Pharmaceuticals Completes Enrollment in Second Fidaxomicin Phase 3 Clinical Trial in Patients With Clostridium difficile Infection
- Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
- Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) reports Q3 loss of $0.28, 9 cents better than the analyst estimate of ($0.37). Revenue for the quarter was $176,202, which compares to the estimate of $210,000.
Related Categories
EarningsStocks Mentioned
-0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
